FDA grants Breakthrough Therapy Designation for Roche ’s Gazyva (obinutuzumab) in Lupus Nephritis

Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva ® (obinutuzumab) for adults with lupus nephritis.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news